Katey Einterz Owen

Katey Einterz Owen, Ph.D. has end-to-end responsibility for the investment portfolio in controlling, eliminating, and eradicating the diseases of the London Declaration. This includes active investment in lymphatic filariasis, onchocerciasis, schistosomiasis, STH, guinea worm, HAT, and visceral leishmaniasis, diseases that collectively put at risk approximately one billion people in the world. The portfolio funds projects with global private and public partners across the value chain, from research and innovation through on-the-ground delivery of interventions in Africa and Asia.

Previously, Katey was the deputy director for Vaccine Development at the foundation, working with partners across sectors to drive innovation, execution, and sustainability in vaccine development, commercialization, and distribution of affordable, fit-for-purpose, safe and effective vaccines for the poorest countries in the world. Disease targets included polio, rotavirus, pneumonia, HIV, malaria, TB, Ebola, HPV, typhoid, ETEC, and shigella. Katey joined the foundation in 2013 from the pharmaceutical industry after demonstrating success in vaccine development, manufacturing, and commercialization across a portfolio of vaccines. She combines a technical end-to-end view of product development and quality manufacturing with a commercial understanding of the for-profit pharmaceutical business, coupled to a solutions-focused mindset and disposition. Her perspectives have also been shaped by her oldest sister, who spent her career as a primary care physician and health-district chief in rural northern Cameroun.

Prior to joining the pharmaceutical industry, Katey carried out academic research on influenza at the National Institute for Medical Research in Mill Hill (London). She earned her Ph.D. in molecular virology from Purdue University.